BriaCell to effect 1-for-10 share consolidation on August 25

BriaCell (BCTX) Therapeutics announced that the Company’s board of directors has approved the consolidation of the Company’s issued and outstanding common shares on the basis of one post-Consolidation Common Share for every ten pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market. The Consolidation is subject to approval by the Toronto Stock Exchange and Nasdaq and is expected to become effective on August 25, 2025, with the post-Consolidation Common Shares commencing trading on the TSX and the Nasdaq at market open on or about August 25, 2025, subject to final confirmation from the TSX and the Nasdaq. No fractional Common Shares will be issued in connection with the Consolidation. Any fractional Common Shares remaining after the Consolidation that are less than 1/2 of a Common Share will be cancelled, and each fractional Common Share that is at least 1/2 of a Common Share will be rounded up to one whole Common Share. The Company does not intend to round up fractional shares at the beneficial level and will instead round any such fractional shares up at the participant level. The exercise or conversion price and/or the number of Common Shares issuable under any of the Company’s outstanding convertible securities will be proportionately adjusted in connection with the Consolidation.